Gilead Sciences (NASDAQ:GILD)

Why Argus Is Taking a Step Back on Gilead Sciences

Gilead Sciences Inc. (NASDAQ: GILD) saw its shares take a step back on Monday after an independent research firm downgraded the stock. Many investors have hoped that the shares will ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Best Buy, Equifax, Gilead, MongoDB, NVIDIA, Rio Tinto, Teva, UPS and More

Stocks were indicated to open lower on Monday, with all major U.S. equity indexes down about 0.3% on average. What investors still need to consider is that the stock indexes ...
Read Full Story »

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the most recent settlement date, October 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Despite Poor Earnings Reaction, Analysts Still See Upside for Gilead

A flurry of biotech giants reported earnings this past week, and for the most part they all took a step back, but none more than Celgene, which saw its shares ...
Read Full Story »

Gilead Earnings Bring Mixed Results

Gilead Corporation (NASDAQ: GILD) has joined other biotech giants in releasing its earnings for the third quarter of 2017. The company's market cap was last seen at $101 billion before ...
Read Full Story »

Short Sellers Chase Biotechs Higher

The short interest data are out for the most recent settlement date, October 13. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Celgene, Gilead, Biogen and More Major Biopharmas Reporting This Week

Third-quarter earnings reporting season is now well under way. So far, things are looking good. The health care sector has yet to see any significant earnings representation, but that will ...
Read Full Story »

Does Gilead’s CAR T Approval Vindicate the High Acquisition Price for Kite Pharma?

Gilead Sciences Inc. (NASDAQ: GILD) has seen many analysts raise their price targets in recent weeks, and now there is a new U.S. Food and Drug Administration (FDA) approval that ...
Read Full Story »

Are Analysts Secretly Calling Gilead a Screaming Buy?

Sometimes it turns out that great growth companies eventually run into the day when getting the growth of the past is not possible. That has been the case of Gilead ...
Read Full Story »

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the most recent settlement date, September 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AbbVie, Amazon, Facebook, Johnson & Johnson, Schlumberger, Visa, Walmart and More

Stocks were indicated to open marginally lower on Wednesday morning, but that is after the Dow hit new all-time highs on Tuesday and has come within 170 points of hitting ...
Read Full Story »

Top Analyst Upgrades and Downgrades: CarMax, DowDuPont, Gilead, GrubHub, Microsoft, Nike, Western Digital and More

Stocks were indicated to open higher on Thursday after small gains on Wednesday, and all major equity indexes remain at or close to all-time highs. The dominating trend of this ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Freeport-McMoran, Gilead, FuelCell, Oracle, Take-Two, Tesla, Waste Management and More

Stocks were indicated to open lower on Wednesday, but this is on the heels of having hit all-time highs into and right after the start of the fourth quarter. The ...
Read Full Story »

Thursday’s Biggest Winners and Losers in the S&P 500

September 28, 2017: The S&P 500 closed up 0.1% at 2,510.06. The DJIA closed up 0.18% at 22,381.16. Separately, the Nasdaq was flat at 6,453.45. Thursday was a relatively mixed ...
Read Full Story »

Short Sellers Hike Bets in Major Biotechs

The short interest data are out for the most recent settlement date, September 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »